Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3

International Journal of Cancer

Volumn 100, Issue 5, 2002, Pages 507-514

  Magklara, Angeliki ^a,b   Brown, Theodore J ^a,b,c   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Androgen receptor; Breast cancer; Co activators; Co repressors; Human glandular kallikrein; Prostate specific antigen

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; COMPLEMENTARY DNA; KALLIKREIN; KALLIKREIN 2; KALLIKREIN 3; UNCLASSIFIED DRUG;

ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA SEQUENCE; ENHANCER REGION; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KALLIKREINS; NUCLEAR PROTEINS; PROTEIN BINDING; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE KALLIKREINS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0037055539     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10520     Document Type: Article

References (52)

1. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element
2. Tissue-specific and hormonal regulation of human prostate specific glandular kallikrein
3. The new human kallikrein gene family: Implications in carcinogenesis
4. Prostate-specific antigen - Its usefulness in clinical medicine
5. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4-10 ng/mL
6. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA
7. Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis
8. Non-prostatic sources of prostate-specific antigen
9. Human glandular kallikrein (hK2) in breast milk, amniotic fluid and breast cyst fluid
10. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids
11. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age
12. Detection of prostate-specific antigen immunoreactivity in breast tumors
13. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer
14. Antiangiogenic activity of prostate-specific antigen
15. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
16. Expression of prostate specific-antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
17. Expression of a prostate associated protein, human glandular kallikrein (hK2) in breast tumors and in normal breast secretions
18. Improved measurement of androgen receptors in human breast cancer
19. Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues
20. Androgen receptors in operable breast cancer: Relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment
21. Androgens induce divergent proliferative responses in human breast cancer cell lines
22. Androgen sensitivity of the new human breast cancer cell line MFM-223
23. Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines
24. Nuclear receptor co-activators: Multiple enzymes, multiple complexes, multiple functions
25. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor
26. Immunocytochemical detection of androgen receptor in human temporal cortex: Characterization and application of polyclonal androgen receptor antibodies in frozen and paraffin-embedded tissues
27. 3H]methyltrienolone (R1881) in the presence of progesterone receptors
28. The attraction of proteins for small molecules and ions
29. LIGAND: A versatile computerized approach for characterization of ligand-binding systems
30. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity
31. Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer
32. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression
33. Androgen receptor in human prostate carcinoma LNCaP/ADEP cells contains a mutation which alters the specificity of the steroid dependent transcriptional activation region
34. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
35. Coactivator and corepressor complexes in nuclear receptor function
36. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription
37. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1
38. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
39. The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator
40. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor
41. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate
42. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells
43. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells
44. FHL2, a novel tissue-specific coactivator of the androgen receptor
45. PDEF, a novel prostate epithelium-specific Ets transcription factor, interacts with the androgen receptor and activated prostate specific-antigen gene expression
46. The small nuclear GTPase Ran: How much does it run?
47. Molecular defects of the androgen receptor
48. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy
49. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
50. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones
51. Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE113 isoform
52. From estrogen to androgen receptor: A new pathway for sex hormones in prostate